Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-Related Bloodstream Infections

NCT00027248 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1400

Enrollment

INDUSTRY

Sponsor class

Conditions

Sepsis
Bacteremia
Fungemia

Interventions

DRUG: MBI 226

Sponsor

BioWest Therapeutics Inc